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Abstract Cisplatin is used to treat a variety of tumors, but
dose-limiting toxicities or intrinsic and acquired resistance
limit its application in many types of cancer including breast.
Cisplatin was attached to silica nanoparticles using
aminopropyltriethoxy silane as a linker molecule and charac-
terized in terms of size, shape, as well as the dissolution of
cisplatin from the silica surface. The primary particle diameter
of the as received silica nanoparticles ranged from 20 to 90 nm.
The results show that adverse effects on cell function, as
evidenced by reduced metabolic activity measured by the
MTT assay and increased membrane permeability observed
using the live/dead stain, can be correlated with surface area
of the silica. Cisplatin-functionalized silica nanoparticles with
the highest surface area incited the greatest response, which
was almost equivalent to that induced by free cisplatin. More-
over, if verified by further studies, would indicate that cisplatin
was attached to silica nanoparticles might prove to be useful in
site-specific drug delivery.
Keywords Silica .Cisplatin .TEM .Nanoparticles .MCF-7
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1 Introduction
Worldwide, deaths: an estimated 39,920 breast cancer deaths
(39,510 women, 410 men) are expected in 2012. Breast
cancer ranks second as a cause of cancer death in women
(after lung cancer) (American Cancer Society 2012). Cis-
diamminedichloroplatinum (II), known as cisplatin, a
platinum-based drug, is one of the most potent antitumor
agents has been widely used in the clinic to treat a variety of
cancers such as ovarian, breast, bladder, head and neck, and
small cell lung cancer because of its potent activity to cross-
link DNA upon entering the cells (Wang and Lippard 2005).
Chemotherapy is the mainstay treatment for advanced and
metastatic disease. DNA-damaging agents have a long and
proven record as anticancer drugs (Decatris et al. 2004). It is
proved that after both passive and active cellular uptake,
cisplatin may react with the N7 atom of guanine in DNA to
form adducts and causes cellular apoptosis (Giese and Mc-
Naughton 2003). However, chronic cisplatin usage results in
resistance by several possible mechanisms including in-
creased interactions with metal lothionein and glutathione
as well as increased DNA repair (Reedijk 2003). To coun-
teract resistance, which lowers the efficiency of cisplatin
significantly, very high systemic doses of cisplatin are ad-
ministered. Unfortunately, such high dose of cisplatin results
in severe systemic toxicity and poor patient compliance,
including nausea/vomiting, renal toxicity, gastrointestinal
toxicity, peripheral neuropathy, asthenia, and ototoxicity,
thus limiting its clinical use (Hill and Speer 1982; Rosenberg
1977). To improve the efficacy and safety of cisplatin, a
variety of methods are applied to drug delivery system,
which include particulate carriers, such as liposomes, poly-
mers, and nanoparticles (NPs) (Bontha et al. 2006; Junior
et al. 2007; Geng et al. 2004). The drug carriers may con-
centrate in the tumor because tumors exhibit a unique en-
hanced permeability and retention effect for 50–100 nm
particles. As a result of this, a large increase in tumor drug
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concentrations (tenfold or higher) could be achieved relative
to administration of the same dose of free drug, (Maeda et al.
2000) thereby decreasing the massive systemic side effects
of conventional chemotherapy. In our previous study on
modified silica nanoparticles, (ORMOSIL, LSN) however,
it was shown that the cytotoxicity across the MCF-7 cells as
measured by methyl-thiazol tetrazolium salts (MTT) assay
was significantly reduced for the case of silica nanoparticles
synthesized and p53 gene delivery successful in breast can-
cer cell line (Rejeeth et al. 2012a; Rejeeth et al. 2012b). In the
case of materials in combination, the relevant question is
whether apparently non-toxic particles are transformed into a
potentially toxic material if surface attached with known toxic
molecules. Three possibilities exist: the nanoparticle/toxic
molecule combination becomes more toxic, the toxicity of
the combination is unchanged, or the toxicity of the combina-
tion is reduced compared to the toxic molecule alone. One
common chemical used for surface functionalization is
aminopropyltriethoxysilane (APTES), which has the chemical
formula NH2 (CH2)3–Si (OC2H5)3 (Gan et al. 2009; Liu et al.
2009; Jang and Liu 2009; Libertino et al. 2008). The silane
end of the APTESmolecule binds covalently to surface silicon
atoms, and the amino end of the molecule increases protein
adsorption on the surface by electrostatic interactions. The
structural transition of a single dsDNA molecule immobilized
on an APTES-treated substrate has been demonstrated. DNA
binding to the APTES linker is much stronger than that on an
alkylthiol/substrate (Nguyen et al. 2009). Silica–cisplatin sys-
tem provides a unique opportunity to explore effects of surface
area, in terms of the ability of nanoparticles to serve as carriers.
The testable hypothesis herein is that nontoxic nanoparticles
with a surface-attached toxic molecule would then adversely
affect cell function, defined here by reduced metabolic activity
and increased membrane permeability. Specifically, these ad-
verse effects are expected to increase with increasing surface
area. Results of physicochemical characterization of the
nanoparticles and nanoparticle/cisplatin combination including
surface area and cisplatin dissolution rates are presented. Ef-
fects on metabolic activity as measured via the MTTassay, and
membrane permeability observed by fluorescence microscopy
using the DAPI/JC-1 live/dead stain, we demonstrated that
these silica-cisplatin prodrug conjugate NPs had well-
controlled drug loading yield, excellent acid-responsive drug
release characteristics, and potent cytotoxicity against breast
cancer.
2 Materials and methods
2.1 Materials
The chemicals, i.e., APTES (3-aminopropyl) triethoxysilane,
Triton X-100, Cisplatin, DAPI and JC-1 (Sigma-Aldrich) were
used without further purification. All the glassware (glass bottle
and small pieces of glass substrate) was cleaned and sonicated
in ethanol for 5 min, rinsed with double-distilled water, soaked
in a H2O/HNO3 (65 %)/H2O2 (1:1:1, v/v/v) solution, rinsed
again with doubly distilled water, and finally dried in air. The
MCF-7 cells were purchased from National Centre for Cell
Sciences (NCCS), Pune, India.
2.2 Surface attachment of cisplatin to silica particles
Approximately, 0.64 g of APTES-functionalized Triton X-
100, silica particles were kept in a three-necked flask respec-
tively and dispersed in 50 mL distilled water with constant
stirring for sample; 0.385 g of cisplatin was added for
APTES-functionalized Triton X-100 samples of suspended
silica particles, respectively. These amounts correspond to
sufficient cisplatin to react with all available silanol groups
(2.5 nm−2) on the surface of silica. The suspended particles
were constantly stirred under nitrogen over-night at room
temperature inside the fume hood. Cisplatin-functionalized
silica particles were then collected by centrifugation at
3,500 rpm for 15 min. Harvested particles were dried at room
temperature and stored in glass bottles for further analysis.
2.3 FT-IR of cisplatin-functional silica nanoparticles
Fourier transform infrared (FT-IR) spectroscopy of silica
nanoparticle, cisplatin, and cisplatin-functionalized silica
nanoparticles were performed by using Nicolet 5700 instru-
ment (Nicolet Instrument, Thermo Company, USA) with
KBr pellet method. Each KBr disk was scanned over a wave
number region of 500–4,000 cm−1 with the resolution of
4.0×108 cm.
2.4 Cisplatin estimation
The platinum content of cisplatin-functionalized silica parti-
cles was measured by inductively coupled plasma-mass
spectrometry (ICP-MS) measurements; 0.020 g of cisplatin
functionalized silica particles was added to 25 mL of 2 %
HNO3. The suspension was sonicated in an ultrasonic bath
for 30 min. After centrifugation, a clear supernatant was
obtained which was analyzed for total platinum (Pt). The
platinum content of the sample was determined by compar-
ison with a platinum standard which was prepared by dilu-
tion of a standard solution of platinum of defined concentra-
tion. The total amount of platinummeasured from the sample
was converted into the amount of cisplatin.
2.5 Transmission electron microscopy
Particle morphology was observed using a field emission
transmission electron microscope (TEM). The selected area
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diffraction patterns of the samples were recorded using the
same TEM instrument. The sample preparation procedure
used for TEM analysis of the particles was as follows. The
particles were first dispersed in ethanol 0.1 mg/mL suspension
in a glass beaker and beaker was sonicated for 10 min. One
drop of sample suspension was placed on a carbon-coated grid
(Ted Pella, USA) and dried at room temperature overnight
before analysis under TEM.
2.6 Particle size analysis with dynamic light scattering
Dynamic light scattering (DLS) was performed using a
Photocor-FC light-scattering instrument employing a 5 mW
laser light source at 633 nm and a logarithmic correlate
instrument to determine the mean equivalent hydro-
dynamic diameters of the samples. For the analysis, a sus-
pension of ~0.1 mg/mL concentration of silica sample was
made in ethanol. The suspension was sonicated for 30 min
prior to analysis. The instrument measures the change of
intensity of the laser light with time at 90° angles after
interaction with spherically shaped particles suspended in
liquid media. The diffusion coefficient was determined from
the correlation function, and, assuming the Stokes–Einstein
equation is valid, the equivalent hydrodynamic diameter
distribution was obtained using the Dyna-LS software pack-
age supplied by Photocor.
2.7 Dissolution of cisplatin from silica particles
Dissolution of cisplatin from the surface of silica particles was
studied in phosphate-buffered saline (PBS) with pH 7.4, at
room temperature (25 °C). In this study, ~30 mg of cisplatin-
functionalized silica samples were suspended in 50 mL of
PBS for 48 h in a conical flask. Ten milliliters of the sample
was taken at the end of the specified time period (24, 36, and
48 h). Sample was centrifuged at 3,500 rpm for 15 min, and
the supernatant was collected. Clear supernatant was analyzed
for platinum using the inductively coupled plasma mass spec-
trometer. A 10-mL volume of fresh dissolution medium (PBS
solution) was added to make up the volume after withdrawal
of sample. The dissolution rate constant of the cisplatin from
the silica surface at different time points (24, 36, and 48 h) was
calculated using the modified Noyes and Whitney equation
(Wurster and Taylor 1965).
dC
dt
¼ Ak Cs−Cð Þ
where, dC/dt=rate of dissolution, A=surface area of the par-
ticle, C=concentration of the cisplatin in the PBS buffer at
25 °C, Cs=saturation concentration of the cisplatin in the PBS
at 25 °C, k=dissolution rate constant, which is defined as
k=D/h, where D=diffusion rate of cisplatin, and h=diffusion
layer thickness.
2.8 Cell culture
The breast cancer cells (MCF-7) were maintained in
Dulbecco’s modified eagles medium (DMEM) supplemented
with 2 mM L-glutamine and balanced salt solution adjusted to
contain 1.5 g/L Na2CO3, 0.1 mM nonessential amino acids,
1 mM sodium pyruvate, 2 mM L-glutamine, 1.5 g/L glucose,
10 mM (4-(2-hydroxyethyl)-1-piperazineethane sulfonic ac-
id), and 10 % fetal bovine serum (GIBCO, USA). Penicillin
and streptomycin (100 IU/100 μg) were adjusted to 1 mL/L.
The cells were maintained at 37 °C with 5 % CO2 in a
humidified CO2 incubator.
2.9 Metabolic activity assay
The mitochondrial activity of MCF-7 cells was measured
after treatment with the cisplatin-functionalized silica sam-
ples using the MTT assay. This test was performed on MCF-
7 cells after 24, 36, and 48 h of incubation with the samples,
as described by (Mosmann 1983). Cells were grown in a 24-
well plate in DMEM media with 10 % fetal bovine serum at
37 °C and 5 % CO2. In this study, silica/cisplatin particles
were added with the weight ranging from 13 to 144 μg/mL
corresponding to the amount needed to give a concentration
of surface attached cisplatin equal to 5 μg/mL in each well of
a single 24-well plate. Four replicates were performed for
each sample. Positive and negative controls were included
on each plate. The MTT assays involved the following steps:
the growth medium was removed from the culture wells and
washed with 300 μL PBS once. After washing, 300 μL of
MTT solution (0.5 mg/mL) was added in each well of the
plate. For the reduction of tetrazolium salt, plates were
Fig. 1 Scheme shows the synthesis of cisplatin-functionalized silica nanoparticles complex
Cisplatin-functionalized silica nanoparticles for cancer 129
incubated at 37 °C for 2 h. The tetrazolium salt was reduced
to a formazan (blue) product by the active mitochondria of
the cells. In each well, 300 μL of solubilizing buffer (10 %
Triton X-100 with 0.1 N HCl in anhydrous isopropanol) was
added to dissolve the reduced tetrazolium salt. The color of
reduced salt was measured at 570 nm using microplate reader
(SpectraMax M5, Molecular Devices, Sunnyvale, CA). The
absorbance at 570 nm was taken as the index of mitochon-
drial activity.
2.10 Fluorescence microscopy
Cellular viability produced by the combination of cisplatin
and silica particles was examined using fluorescence micros-
copy after staining the MCF-7 cell with the live/dead system
(Molecular Probes, USA). After incubation with the samples
in 96-well plates, cells were stained by adding DAPI and JC-
1 to reach a final concentration in the well plates of 4 μM
DAPI and 2 μM JC-1. DAPI undergoes fragment DNA
conversion to fluorescent DAPI (blue, 340 nm wavelength),
which is retained well within live cells. JC-1 enters cells with
damaged membranes, and undergoes a fluorescence en-
hancement (brown, 635 nm wavelength) upon binding to
DNA fragments. Cells were incubated with the dyes for
20 min in 100 μL PBS, and imaged under the fluorescence
microscope (Nikon instrument Inc., USA) using an excita-
tion wavelength of 488 nm.
2.11 Cell sectioning for electron microscopy
Cisplatin-functionalized silica-treated MCF-7 cell line was
grown on the 24-well cell culture plates. MCF-7 cells exposed
to silica (Triton X- 100) were used as the control. Cells were
washed with PBS buffer and collected in centrifuge tubes after
harvesting. Cells were washed with 0.13 M phosphate buffer
three times for 10 min. At the end of the washing, cells were
treated with a fixative solution (2% glutaraldehyde) overnight at
4 °C. After fixation, cells were washed with 0.1 M phosphate
buffer three times for 10 min to remove the excess glutaralde-
hyde. Cells were post-fixed with 1 % OsO4 in PBS for 60 min
and washed with double-distilled water three times for 10 min.
After washing, cells were dehydrated at room temperature in 30,
45, 65, 90, and 100 % ethanol for 10 min each. Cells were then
infiltrated with propylene oxide and LR white resin mixture for
4 h. Cells were kept in fresh pure LR white resin overnight at
room temperature. Finally, the cells were embedded in capsules
Fig. 3 a Transmission electron microscope image of cisplatin-func-
tionalized silica particles. b Selected area electron diffraction and higher
magnification image
Fig. 2 Diameter measured by
dynamic light scattering for
cisplatin-functionalized silica
nanoparticles
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(ElectronMicroscopy Sciences, USA) with freshly prepared LR
white resin. Polymerization was carried out in an oven at 60 °C
for 24 h. Sections from the embedded cells were cut on an Ultra
cut microtome (Reichert, Wien, Austria) and collected on 100-
mesh copper TEM grids (Ted Pella Inc.,). Ultrathin sections
mounted on copper grids were stained with 1 % aqueous uranyl
acetate (Ted Pella Inc.,) for 15 min and lead citrate (Electron
Microscopy Sciences, USA) for 1.5 min.
2.12 Statistical analysis
Appropriate statistical procedures (Student t test for means,
Stat graphics plus 3.3 software) were applied in the statistical
analysis of the experimental data.
3 Results and discussion
3.1 Synthesis and characterization of cisplatin-functionalized
silica particles
In this study, schematic diagrams shows (Fig. 1) the surface of
silica particles was modified by the attachment of cisplatin
molecules, making use of the silanol groups on the silica
surface. Silanol groups are thought to be predominantly iso-
lated from each other, with the surface concentration reported
to vary between two and four silanol groups per square
nanometer (Fripiat 1982; Iler 1979; Katz and Milewski
1987; Mathias and Wannemacher 1988). In a study of silica,
the silanol surface concentration was found to vary only
slightly with surface area: 2.1 groups/nm2 for Triton X-100,
which is made at high flame temperatures to facilitate larger
primary particle diameters, versus 2.4–2.5 groups/nm2 report-
ed for Aerosil samples (Bhowmick et al. 2010). The observed
reductions in the specific surface areas of the cisplatin-
functionalized particles are explained by the attachment of
cisplatin molecules on the particle surface. The mean equiva-
lent hydrodynamic diameters of cisplatin-functionalized silica
samples, as determined by DLS, are given in Fig. 2. Smaller
particles, with respect to hydrodynamic diameter, have a
greater surface area and are more easily dispersed in aqueous
solutions, because of the presence of higher concentration, on
a per gram of silica basis, of silanol groups on the surface of
the higher specific surface area.
Silica particle morphology was observed using TEM. The
TEM image of the cisplatin-functionalized silica sample in
Fig. 3a shows particles that are round in shape, ranging from
20 to 90 nm in diameter. The electron diffraction pattern,
given in Fig. 3b (inset), shows the amorphous nature of the
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Fig. 5 Estimation of maximum
and minimum cisplatin
attachment to the silica surface
and inductively coupled plasma




Fig. 4 FT-IR spectra, before and after the reaction with cisplatin-
functionalized silica nanoparticles. a Silica nanoparticles, b cisplatin,
c cisplatin-functionalized silica nanoparticles
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be platinum, are uniformly distributed on the surface of the
particles. Mapping of the platinum also suggests a relatively
uniform distribution of platinum on the silica particles. Ox-
ygen and silicon result from the silica particles, and carbon
from the TEM grid support and/or the APTES linker mole-
cule on the particles.
3.2 FT-IR characterization of cisplatin-functionalized silica
nanoparticles
Figure 4a shows the FT-IR spectra of silica nanoparticles, the
characteristic property of silica nanoparticles was showed by
the N–H and O–H stretching vibration at 3,607 cm−1 and the
SiH3OH bending vibration at 1,622 cm
−1. The broad band
spectrum at 2,977 and 1,639 cm−1 shows the presence of
cisplatin (Fig. 4b). The PEGs bending vibration at 1,639 cm−1
demonstrating the characteristic property of cross-linked silica
nanoparticles functionalized with cisplatin. The characteristic
peak at 1,565 and 1,386 cm−1 clearly reveals bending vibration
of SiH3OH and stretching vibration of PEGs, respectively. The
characterized small peak at 1,565 and 1,490 cm−1 shows the
HCL removed stretching of cisplatin-functionalized silica
nanoparticles (Fig. 4c). This result clearly shows the cross-
linking of cisplatin-functionalized silica nanoparticles
(supporting data S3).
3.3 Amount of cisplatin attached to the silica surface
ICP-MS results for the amount of cisplatin attached to the
silica surface are presented in Fig. 5, along with estimates of
the minimum and maximum expected cisplatin loading. The
maximum amount of cisplatin attachment to the silica parti-
cles was estimated assuming that silica particles contain
2.5 silanol groups/nm2 on the surface (Katz and Milewski
















































































Fig. 7 MTT assay of cisplatin-functionalized silica particles on MCF7. a
After 24, 36, and 48 h and b dose-dependent study of free cisplatin. Results
are presented as mean values compared to the control, and error bars
represent standard deviation of four experiments. Asterisks denote statisti-


















































Fig. 6 a Percentage cisplatin dissolved as a function of time. b Disso-
lution rate of cisplatin from the surface of silica particles to PBS buffer
estimated by inductively coupled plasma-mass spectrometry. Error
bars represent standard deviations of triplicate measurements
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groups, APTES, and cisplatin. A minimum amount of cis-
platin attachment was estimated assuming that 50 % reaction
had occurred between the silanol groups and APTES, and
between APTES and cisplatin. As shown in Fig. 5, the
cisplatin loading is projected to be roughly proportional to
the surface area of the silica nanoparticles. This was ob-
served experimentally, with cisplatin loading ranging from
maximum 0.4 g cisplatin/g silica for APTES to 0.039 g
cisplatin/g silica for silanol groups. These results indicate
the significance of nanoparticle-based materials in terms of
their high loading capacity.
3.4 Dissolution of cisplatin from silica particles
Cisplatin-functionalized silica particles were used to investi-
gate the release of cisplatin in PBS buffer (pH 7.4) with time.
The percentages of cisplatin released from functionalized
silica samples are shown in (Fig. 6a) and the dissolution rate
constants of cisplatin from the samples are shown in Fig. 6b.
The solubility of cisplatin in water is 2,350 mg/L (Kim et al.
2009). As shown in Fig. 6a, the percentages of cisplatin
released are low but non-zero. In Fig. 6b, it can be seen that
the dissolution rate constant of cisplatin from the cisplatin-
Fig. 8 Live/dead images of
MCF7 cells viewed under the
fluorescence microscope after
interaction with a control, b
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functionalized silica particles is ten times greater than that of
the lower specific surface area of surfactant (supporting data
S1) 50 samples at 24 h. It can also be observed that the
cisplatin dissolution rate decreases with time for all of the
cisplatin-functionalized samples. Results also indicate that the
dissolution of cisplatin in PBS buffer from the particle sur-
faces does not reach equilibrium within 48 h of time. This
higher dissolution rate constant of cisplatin from the cisplatin-
functionalized silica nanoparticles is attributed to the higher
specific surface areas of the particles compared to the other
samples (supporting data S2).
3.5 In vitro effects on metabolic function
We evaluated the effects of cisplatin-functionalized silica
nanoparticles and cisplatin alone on cellular metabolic activ-
ity using the MTTassay after 24, 36, and 48 h, and the results
are presented in Fig. 7a. MTT results for different doses of
free cisplatin after 48 h are represented in Fig. 7b. Significant
differences (p≤0.05) between control and sample, as denot-
ed by asterisks in Fig. 7a, were observed for the surface area
samples, Triton X-100-cisplatin, at the earlier time points.
Significant differences between control and sample were
observed for silica–cisplatin samples by 48 h. The MCF-7
cells exhibits the smallest decrease in metabolic activity in
the case of cisplatin-functionalized silica sample, even after
48 h of incubation. Student t test indicates that the MTT
results for each of the silica samples and the 5 μg/mL cis-
platin sample are significantly different (p≤0.05). Results
also show that reduction in metabolic activity after treatment
with the Triton–cisplatin construct (45 % compared to con-
trol) is very close to the response from the cells treated with
cisplatin (38 % compared to control). An almost equal re-
duction in metabolic activity can be observed after 48 h when
the cells are incubated with free cisplatin at different doses
(0.1–10 μg/mL) as shown in Fig. 7b. With the silica–cisplat-
in system, it is important to note, however, that no apparent
synergistic effects were observed in terms of adverse effects
on cellular function, unlike in prior reports of the
benzo(a)pyrene/iron oxide micron-sized particle system
(Garcon et al. 2001; Garry et al. 2004). Nor were any miti-
gative effects on cellular function observed, as in the case of
silica synthesized with chitosan, compared to silica synthe-
sized in the absence of chitosan (Chang et al. 2007). Expo-
sure to the combination of cisplatin with silica that had the
highest specific surface area resulted a similar effect on
metabolic activity as compared to exposure to the equivalent
amount of free cisplatin.
The MCF-7 cells were treated with cisplatin-functionalized
silica particles of specific surface area for 24 h, and viability was
observed by staining live and dead cells with DAPI and JC-1,
respectively. Fluorescence stained breast cancer cells after treat-
ment with the control (nontreated), Triton X-100 silica particles,
cisplatin-functionalized particles, and free cisplatin are shown in
Fig. 9 Transmission electron
microscope images of MCF7
cells a after interaction with
cisplatin-functionalized silica
particles, inset shows
extracellular particles, b the same
sample suggesting endocytosis
of the silica particles, inset shows
particles at higher magnification,
c and d control cells showing a
smaller nucleus compared to the
cisplatin-functionalized particle-
treated cell
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Fig. 8a, b, c, and d respectively. Remarkable morphological
changes were observed under the fluorescence microscope
when cells were treated with cisplatin-functionalized particles.
In Fig. 8d, the number of cells remaining after treatment with
the particles is less than the others. The MTT results also have
shown that the greatest reduction in metabolic activity was
produced by the treated cells, which is in agreement with the
fluorescence microscopy images. Results showed that after 24 h
of incubation, cisplatin-functionalized silica particles and free
cisplatin have the strongest adverse effect on viability compared
to the control. In the fluorescence images, most of the cells
appeared dead after treatment with cisplatin-functionalized silica
particles and free cisplatin, Fig. 8c, d. In contrast, treatment with
control (nontreated) led to slate significant adverse effects in the
cells; most of the cells are alive as shown in Fig. 8a. This study
indicates that nanoparticle-mediated morphological alteration
may occur in the cells and to study these morphological changes
at a higher level of resolution, we further observed them in the
transmission electron microscope.
3.6 Cellular response to cisplatin-functionalized silica
particles
Cisplatin-functionalized silica particle breast cancer cell in-
teractions were investigated by TEM analysis of thin sec-
tioned cell samples. Representative micrographs are shown
in Fig. 9, with images chosen after analyzing 50–100 cells
from each sample. The morphology of MCF-7 cells after
treatment with cisplatin-functionalized silica particles is
shown in Fig. 9a, b whereas MCF-7 cells after treatment
with control silica particles are shown in Fig. 9c, d. TEM
images clearly show the internalization of the both control
and cisplatin-functionalized silica particles inside the cells
(Fig. 9c). In both the cases, extracellular particles are also
visible in the images. Images also show that intracellular
particles are confined inmembrane-bound vacuoles (Fig. 9a).
Internalized particles are found in aggregated form and may
have entered the cells by the endocytosis process as sug-
gested by the image in Fig. 9b. Membrane-bound aggregated
particles are observed to be very close to the nucleus of the
cell in some cases. The morphological changes in MCF-7
cells after 48 h of growth are also shown in Fig. 9. The
images shown in Fig. 9 are the representatives of entire cell
population after analyzing 50–100 cells in each sample.
Images of cells after treatment with control silica particles
(Fig. 9c, d) revealed that the cell membranes are more
integrated compared to the cells treated with cisplatin-
functionalized silica particles (Fig. 9a, b). It also can be
observed that nucleus of the cells treated with cisplatin-
functionalized silica (Fig. 9a) is much larger compared to
the cells treated with control silica particles (Fig. 9c) (Meijer
et al. 2001).
TEM analysis of the MCF-7 cells can shed light in under-
standing the possible interaction mechanisms of cisplatin-
functionalized silica particles with the cells. Cisplatin must
be able to react with DNA to affect cell function, so it needs to
reach the cell nucleus. In the TEM images, both extracellular
and intracellular particles are visible suggesting two possibil-
ities. The extracellular particles may be releasing cisplatin into
solution, which is then taken up by the cells. Free cisplatin is
believed to enter cells via both passive and active transport
routes (Ohmori et al. 1993). Cisplatin-functionalized silica
nanoparticles can enhance both possible interaction mecha-
nisms by bringing high loadings of cisplatin near the cells for
passive transport of free cisplatin to take place. The intracel-
lular particles, on the contrary, may carry bound cisplatin into
the MCF-7 cells, which is then released into the cytoplasm
with higher surface area corresponding to greater rates of
active transport.
4 Conclusions
In conclusion, successful attachment of a controlled amount
of toxic cisplatin molecules on the surface of the nano-sized
silica particles was demonstrated and the particles were
characterized in terms of particle size and surface area. In
this study, we have demonstrated that the dissolution rate of
cisplatin from the surface of the particles to the solution
phase depends on the surface areas of the particles. Biolog-
ical studies have shown that, the impaired cellular function in
the MCF-7 induced by cisplatin-functionalized silica parti-
cles, as indicated by the reduced metabolic activity and cell
viability. These effects appeared to be correlated with the
cisplatin functionalized surface areas of the particles. Appar-
ent uptake of the particles by the cells and morphological
differences after active interaction with the cisplatin-
functionalized silica particles were observed by TEM. The
importance of our study lies in showing the combinatorial
effect of relatively high surface area nanoparticles and toxic
molecules at the cellular level. In the wake of increasing use
of nanoparticles, which may be either surface modified prior
to end use in drug delivery constructs or consumer products,
or upon release into the environment, this study issues a
cautionary note that the properties of the nanoparticles, es-
pecially specific surface area, may affect biological response.
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